Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

Tel Aviv Sourasky Medical Center Emergency Department study group

doi:10.1016/j.ejim.2022.03.001

Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

Tel Aviv Sourasky Medical Center Emergency Department study group

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	137-139
Number of pages	3
Journal	European Journal of Internal Medicine
Volume	100
DOIs	https://doi.org/10.1016/j.ejim.2022.03.001
State	Published - Jun 2022

Keywords

BNT162b2 vaccine
Casirivimab/Imdevimab therapy
High-risk patients
SARS-CoV-2 delta variant
Severe outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejim.2022.03.001

Cite this

@article{55e47b3b8ed94ce9bba913e74bced0d6,

title = "Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection",

keywords = "BNT162b2 vaccine, Casirivimab/Imdevimab therapy, High-risk patients, SARS-CoV-2 delta variant, Severe outcome",

author = "{Tel Aviv Sourasky Medical Center Emergency Department study group} and Noah Shopen and Michal Dekel and Michal Mizrahi and Efrat Zandberg and Daniel Talmud and Neta Cohen",

year = "2022",

month = jun,

doi = "10.1016/j.ejim.2022.03.001",

language = "אנגלית",

volume = "100",

pages = "137--139",

journal = "European Journal of Internal Medicine",

issn = "0953-6205",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

AU - Tel Aviv Sourasky Medical Center Emergency Department study group

AU - Shopen, Noah

AU - Dekel, Michal

AU - Mizrahi, Michal

AU - Zandberg, Efrat

AU - Talmud, Daniel

AU - Cohen, Neta

PY - 2022/6

Y1 - 2022/6

KW - BNT162b2 vaccine

KW - Casirivimab/Imdevimab therapy

KW - High-risk patients

KW - SARS-CoV-2 delta variant

KW - Severe outcome

UR - http://www.scopus.com/inward/record.url?scp=85131106343&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2022.03.001

DO - 10.1016/j.ejim.2022.03.001

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 35300887

AN - SCOPUS:85131106343

SN - 0953-6205

VL - 100

SP - 137

EP - 139

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

ER -

Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

Keywords

UN SDGs

Access to Document

Other files and links

Cite this